MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Michael C KirchbergerLucie Heinzerling

Abstract

Melanoma harbours genetic alterations in genes such as BRAF, NRAS and KIT. Activating NRAS mutations are present in about 20% of melanomas. Even though BRAF mutations can be effectively targeted with specific inhibitors, this approach has proven more challenging in cases of NRAS mutations. Previous reports suggested that immunotherapy might be more successful in NRAS-mutated compared to BRAF-mutated or BRAF/NRAS wildtype melanoma. In this study, overall survival and response to anti-PD-1 (nivolumab, pembrolizumab) and anti-CTLA-4 (ipilimumab) therapy of 364 patients with metastatic melanoma were assessed comparing 236 NRAS-mutated patients with 128 NRAS wildtype patients. Subtyping of NRAS mutation in 211 cases revealed 12 different genotypes of which Q61 mutations were predominant (95%). Patients with NRAS mutant melanoma showed similar response rates to checkpoint inhibitor therapy compared to NRAS wildtype patients with 15% versus 13% for ipilimumab (P = 0.731), 21% versus 13% for anti-PD-1 monotherapy (P = 0.210) and 40% versus 39% for ipilimumab and anti-PD-1 therapy in combination or sequence (P = 0.859). Nevertheless, median overall survival of patients with NRAS mutant melanoma was significantly lower with 21 months com...Continue Reading

Citations

Dec 24, 2018·Expert Opinion on Investigational Drugs·Bartosz SzostakAndrzej Pawlik
Dec 18, 2018·Molecular Carcinogenesis·Mariusz L HartmanMalgorzata Czyz
Aug 23, 2019·The British Journal of Dermatology·S M GoldingerR Dummer
Feb 8, 2019·Science Translational Medicine·Alessandro Prestipino, Robert Zeiser
Aug 14, 2019·Pigment Cell & Melanoma Research·Elisa BertoliAlessandro Marco Minisini
Oct 20, 2020·Frontiers in Cell and Developmental Biology·Cheila BritoMarta Pojo
Nov 26, 2019·Journal of Pediatric Hematology/oncology·Victoria MitreRajkumar Venkatramani
Jun 8, 2021·Cancer Treatment Reviews·Tijana RandicStephanie Kreis
Jun 18, 2021·OncoTargets and Therapy·Alejandro Garcia-AlvarezEva Muñoz-Couselo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Gan to kagaku ryoho. Cancer & chemotherapy
Hisashi Uhara
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Selma UgurelDirk Schadendorf
© 2022 Meta ULC. All rights reserved